GSK shuts Stevenage R&D hub
Analysis based on 12 articles · First reported Jul 28, 2026 · Last updated Jul 28, 2026
GSK's restructuring is expected to improve long-term margins and R&D efficiency, but short-term costs and job uncertainty may weigh on sentiment. The move strengthens GSK's presence in a leading life sciences cluster, potentially boosting innovation and competitiveness.
GSK plc announced plans to close its main R&D hub in Stevenage, Hertfordshire, and open a new flagship site in Cambridge as part of a £400 million investment. The move aims to cut annual costs by £1.9 billion over three years to fund R&D and offset the patent expiry of HIV drug dolutegravir. Around 1,800 staff are affected, with a phased relocation to Cambridge or Ware by 2029. The new 300,000 sq ft centre, developed by Prologis, will house over 1,000 scientists within the United Kingdom — Cambridge Biomedical Campus. GSK reported half-year underlying core operating profit up 8% to £5.45 billion, but statutory earnings fell 31% to £2.77 billion.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard